Why Amgen ( AMGN ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Stock Market News for Oct 2, 2025
Wall Street closed higher on Wednesday, driven by healthcare stocks.
2 High-Yield Dividend Growth Stocks to Buy in October and Hold for a Decade or Longer
These stocks have been raising their payouts much faster than most dividend payers.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Amgen Expands US Manufacturing Network Amid New Tariff Policy - Amgen ( NASDAQ:AMGN )
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc ( NASDAQ: AMGN ) announced a $650 million expansion of its U.S. manufacturing network.
Amgen Inc. ( AMGN ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen ( AMGN ) Dips More Than Broader Market: What You Should Know
Amgen (AMGN) closed at $279.22 in the latest trading session, marking a -2.65% move from the prior day.
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity drug battle.
AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire
AstraZeneca wins CHMP backing for label expansions of Koselugo in adult NF1 PN patients and Tezspire in chronic rhinosinusitis with nasal polyps.
European Advisory Panel Recommend Two AstraZeneca Drugs For Approval - AstraZeneca ( NASDAQ:AZN )
AstraZeneca Plc AZN and Amgen Inc.'s AMGN Tezspire ( tezepelumab ) has been recommended for approval in the European Union ( EU ) for adult patients with chronic rhinosinusitis with nasal polyps ( CRSwNP ) .
Amgen ( AMGN ) Moves 3.5% Higher: Will This Strength Last?
Amgen (AMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?
J&J shares gain 17.7% in three months, adding $63B to its market cap. Technical and pipeline momentum fuel investor interest.
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®
REYKJAVIK, ICELAND ( September 22, 2024 ) - Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human ...
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®
REYKJAVIK, Iceland, Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency's ( EMA ) Committee for Medicinal ...
What's Going On With Amgen Stock Friday? - Amgen ( NASDAQ:AMGN )
The European Medicines Agency's ( EMA ) human medicines committee ( CHMP ) has recommended extending the therapeutic indication of Amgen Inc.'s AMGN Uplizna ( inebilizumab ) to include the treatment of adult patients with active immunoglobulin G4-related disease ( IgG4-RD ) .
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why
J&J sees Innovative Medicines growth in 2025, fueled by oncology and immunology drugs, despite steep Stelara sales erosion.
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
Why Amgen ( AMGN ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.
Amgen Inc. ( AMGN ) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
2 Healthcare Dividend Stocks to Buy and Hold
These drugmakers have competitive yields and have increased their dividends at a good clip.
Where Does VKTX Stock Stand After the Obesity Pill Setback?
Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Zai Lab ( NASDAQ:ZLAB )
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products The survival benefits for a new gastric cancer drug, bemarituzumab, were weaker than expected in the final analysis of a Phase Three trial
Is NVO's Major Restructuring Plan an Indication to Sell the Stock?
Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis - Amgen ( NASDAQ:AMGN )
Less than one GI ulceration event per 100 patient-years reported across Phase 3 trials. The majority of patients saw continued skin clearance and itch relief after one year. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On Amgen Inc.
If You'd Invested $10,000 in Amgen Stock ( AMGN ) 3 Years Ago, Here's How Much You'd Have Today
You could have done worse -- or much better.
Amgen ( AMGN ) Stock Slides as Market Rises: Facts to Know Before You Trade
In the most recent trading session, Amgen (AMGN) closed at $280.19, indicating a -1.22% shift from the previous trading day.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Why Is Sanofi Stock Falling Thursday? - Sanofi ( NASDAQ:SNY )
Rocatinlimab showed 10% pyrexia and 6% chills, forcing Phase 3 dosing limits. Amlitelimab had just 1.1% pyrexia and 0.4% chills, with efficacy matching high-dose rocatinlimab. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug - Zai Lab ( NASDAQ:ZLAB ) , Amgen ( NASDAQ:AMGN )
The final analysis of the Phase 3 trial showed reduced survival benefits from bemarituzumab. FORTITUDE-102 readout expected by late 2025 or early 2026 before regulatory filing. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special ) On Wednesday, Amgen Inc.
Investors Heavily Search Amgen Inc. ( AMGN ) : Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Maze Therapeutics, Inc. ( Nasdaq: MAZE ) , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Misbah Tahir ...
Investing in the Age of Longevity: Silver Economy Stocks in Focus
AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.
Here's Why Amgen ( AMGN ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
2 Dividend Stocks to Hold for the Next 10 Years
These stocks offer more than just dividends.
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?
LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.
AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?
Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.
What's Going On With BeOne Medicines Stock Monday? - Royalty Pharma ( NASDAQ:RPRX ) , BeOne Medicines ( NASDAQ:ONC ) , Amgen ( NASDAQ:AMGN )
BeOne to sell Imdelltra royalties for $885 million upfront, plus $65 million option within a year. Royalty deal excludes China, with profit-sharing on sales above $1.5 billion annually. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here → BeOne Medicines ...
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?
Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee - I-MAB ( NASDAQ:IMAB )
Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of Directors Research and Development Committee established to accelerate innovation and long-term growth Dr. Ken Takeshita appointed to the Scientific Advisory Board
Here is What to Know Beyond Why Amgen Inc. ( AMGN ) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.
Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?
J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.
3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade
Some of the highest-yielding stocks in the Dow Jones Industrial Average index look like smart buys for income-seeking investors.
Warren Buffett, Cathie Wood Share 2 Stock Investments In Common: Can You Guess What They Are? - Amazon.com ( NASDAQ:AMZN )
Warren Buffett and Cathie Wood differ on investment styles. There are two stocks currently owned by both legendary investors. Get more market-moving news first with AI-powered analysis that turns noise into opportunity. When it comes to Warren Buffett and Cathie Wood, their investment styles ...
Lilly Stock Down 5% This Month: Should You Buy the Dip?
Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill orforglipron disappointed.
